Logo

Sobi to Acquire Dova Pharmaceuticals for $915M

Share this

M&A

Sobi to Acquire Dova Pharmaceuticals for $915M

Shots:

  • Sobi acquires Dova Pharmaceutical in cash & stock transaction making a total deal value as $915M.  Dova to receive upfront of $27.50/share in cash- $1.50/share on approval of Doptelet as CVR- representing a total consideration of up to $29.00/share with a premium of 36% to Dova’s closing price on Sept 27- 2019
  • The focus of the acquisition is to bolster Sobi’s hematology & orphan diseases portfolio with the addition of Dova’s Doptelet and expand its presence in the US. The transaction is expected to be completed in Q4’19
  • Dova’s Doptelet (avatrombopag) is a second-generation small molecule thrombopoietin receptor (TPO) agonist- act by increasing platelet count to treat thrombocytopenia- currently being evaluated in P-III study for chemotherapy-induced thrombocytopenia (CIT) and has received FDA’s approval for CLD & ITP in May’2018 & Jun’2019 respectively

Source 1- Source2 to­ read full press release/ article | Ref: Sobi- Dova Pharmaceutical | Image: Pharmaceutical Technology


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions